189 related articles for article (PubMed ID: 27801816)
1. Marine Fungi as Producers of Benzocoumarins, a New Class of Inhibitors of Glycogen-Synthase-Kinase 3β.
Wiese J; Imhoff JF; Gulder TA; Labes A; Schmaljohann R
Mar Drugs; 2016 Oct; 14(11):. PubMed ID: 27801816
[TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
4. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
5. Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors.
Hulcová D; Breiterová K; Siatka T; Klímová K; Davani L; Šafratová M; Hošťálková A; De Simone A; Andrisano V; Cahlíková L
Molecules; 2018 Mar; 23(4):. PubMed ID: 29561817
[TBL] [Abstract][Full Text] [Related]
6. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
[TBL] [Abstract][Full Text] [Related]
7. Structural-Based Optimizations of the Marine-Originated Meridianin C as Glucose Uptake Agents by Inhibiting GSK-3β.
Han S; Zhuang C; Zhou W; Chen F
Mar Drugs; 2021 Mar; 19(3):. PubMed ID: 33809065
[TBL] [Abstract][Full Text] [Related]
8. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of GSK-3β Alleviates Collagen II-Induced Rheumatoid Arthritis in Rats.
Zhou H; Liu J; Zeng J; Hu B; Fang X; Li L
Med Sci Monit; 2016 Mar; 22():1047-52. PubMed ID: 27029564
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of GSK-3beta mediates expression of MMP-9 through ERK1/2 activation and translocation of NF-kappaB in rat primary astrocyte.
Kim SD; Yang SI; Kim HC; Shin CY; Ko KH
Brain Res; 2007 Dec; 1186():12-20. PubMed ID: 17996850
[TBL] [Abstract][Full Text] [Related]
11. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
Gao Y; Ye DY; Zhou WC; Chu Y
Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.
Liang Z; Li QX
ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP
Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053
[TBL] [Abstract][Full Text] [Related]
14. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X
J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.
Walz A; Ugolkov A; Chandra S; Kozikowski A; Carneiro BA; O'Halloran TV; Giles FJ; Billadeau DD; Mazar AP
Clin Cancer Res; 2017 Apr; 23(8):1891-1897. PubMed ID: 28053024
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
19. The role of glycogen synthase kinase-3beta in schizophrenia.
Koros E; Dorner-Ciossek C
Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Glycogen Synthase Kinase 3β Alleviates Chronic Renal Allograft Dysfunction in Rats.
Deng J; Wang X; Zhou Q; Xia Y; Xiong C; Shao X; Zou H
Transplantation; 2021 Apr; 105(4):757-767. PubMed ID: 32890133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
